FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial

In its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn't show a “clinically meaningful” benefit. AstraZeneca touted ...